drugset / Trial / NCT05447676
Effects of 4-AP on Functional SCI Recovery
Phase 0
Completed
26 enrolled
Shirley Ryan AbilityLab
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalfampridine | Small molecule | 10 mg | — |